OzUK MDISprint service expands with Ab Initio Pharma Partnership

OzUK Ltd is pleased to announce that it has partnered with Australian-based clinical-trial manufacturer, Ab Initio Pharma to offer a bench-to-clinic service for MDI innovators. OzUK specialises in the development of pressurised metered dose inhaler technology and the management team are inventors of some of the most significant MDI formulation valve, canister, and actuator patents over the past two three decades, commercialising several market leading MDI technologies. The partnership with OzUK will allow clients to seamlessly transfer MDI technology from OzUK’s Respiratory R&D Centre in Chippenham, UK to Ab Initio’s clinical trial production facility in Sydney.

MDISprint provides full R&D and CMC support, IP generation, tech transfer and GMP manufacturing of MDIs for first in human and early phase trials. The modular process of MDISprint means, that as a client, you receive granular data throughout the program, allowing you to make informed strategic business decisions more readily. MDISprint supports both solution and suspension metered dose inhalers innovator and generic products and the use of conventional or novel propellant systems.

Dr William Glover, Chief Operating Officer and Head of Quality at AB Initio Pharma said “Ab Initio is well placed to offer manufacturing services for MDIs. We have a purpose-built state-of-the-art facility for GMP manufacture of clinical trial products and a team with a long track record of successful commercial and trial manufacture… With capabilities to fill a range of MDI products including novel propellants, our partnership with OzUK places us to serve a vibrant clinical trials sector in Australia and overseas.”

Dr David Lewis, Director at OzUK said “recent innovations in the MDI sector are unprecedented; we are seeing more and more clients shift to MDIs as a preferred option for local and systemic delivery and with the advent of novel propellants, we are well placed to generate innovative products with long IP runways”….”our partnership with Ab Initio Pharma will allow us to fast track MDIs R&D to the clinic by offering a full spectrum of services from concept to GMP trial manufacture.

To learn more about the MDISprint, and our Partnership reach out to us at www-oz-uk-labs.com